Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26066037,bioavailability,The bioavailability was 116% relative to Relenza®.,"Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26066037/),%,116,2268,DB00558,Zanamivir
,10429837,maximum serum concentrations,Inhalation of zanamivir gave a broad peak of systemic absorption with mean maximum serum concentrations of approximately 30 to 40 micrograms/L after 1.5 hours.,Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10429837/),[μg] / [l],30 to 40,3595,DB00558,Zanamivir
,26037932,IC50,The bioisosteric amidine 5 turned out to be potently active against a panel of H1N1 (IC50 = 2-10 nM) and H3N2 (IC50 = 5-10 nM) influenza A viruses (NA inhibition assay).,Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26037932/),nM,2-10,5214,DB00558,Zanamivir
,26037932,IC50,The bioisosteric amidine 5 turned out to be potently active against a panel of H1N1 (IC50 = 2-10 nM) and H3N2 (IC50 = 5-10 nM) influenza A viruses (NA inhibition assay).,Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26037932/),nM,5-10,5215,DB00558,Zanamivir
≤,26037932,F,"Unfortunately, both prodrugs were not orally bioavailable to a convincing degree (F ≤ 3.7%, rats).",Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26037932/),%,3.7,5216,DB00558,Zanamivir
,7840556,elimination half-life,"GG167 was metabolically stable, with an elimination half-life of 10 min following intravenous administration.","Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840556/),min,10,25260,DB00558,Zanamivir
,10709152,Relative bioavailability,"Relative bioavailability of the inhaled powder to the intranasal drops and spray was 2.3 and 1.6, respectively.",A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709152/),,2.3,34283,DB00558,Zanamivir
,10709152,Relative bioavailability,"Relative bioavailability of the inhaled powder to the intranasal drops and spray was 2.3 and 1.6, respectively.",A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709152/),,1.6,34284,DB00558,Zanamivir
,21896909,concentration ratios,Median ELF/serum zanamivir concentration ratios ranged from 55 to 79% for intermittent i.v. administration (when sampled 12 h after the last dose) and 43 to 45% for continuous infusion (when sampled 6 to 12 h after the start of the infusion).,Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21896909/),%,55 to 79,37345,DB00558,Zanamivir
,21896909,concentration ratios,Median ELF/serum zanamivir concentration ratios ranged from 55 to 79% for intermittent i.v. administration (when sampled 12 h after the last dose) and 43 to 45% for continuous infusion (when sampled 6 to 12 h after the start of the infusion).,Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21896909/),%,43 to 45,37346,DB00558,Zanamivir
,23436258,elimination half-life (t(1/2) β),"Oseltamivir shows dose linear kinetics, and oseltamivir carboxylate has an elimination half-life (t(1/2) β) after oral administration in healthy individuals of approximately 7.7 hours.",Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436258/),h,7.7,44925,DB00558,Zanamivir
,23436258,t(1/2) β,Zanamivir distributes in an apparent volume of distribution approximating that of extracellular water and is rapidly eliminated (t(1/2) β of approximately 3.0 hours).,Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436258/),h,3.0,44926,DB00558,Zanamivir
,23436258,t(1/2) β,Peramivir is slowly eliminated (t(1/2) β of 7.7-20.8 hours) and is prescribed as either a once-daily injection or as a single infusion.,Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436258/),h,7.7-20.8,44927,DB00558,Zanamivir
,10390212,areas under the curve,"Reductions in the frequency of viral shedding (0% versus 100% in placebo, P < 0.005) and seroconversion (14% versus 100% in placebo, P < 0.005) and decreases in viral titer areas under the curve (0 versus 11.6 [median] log10 TCID50. day/ml in placebo, P < 0.005) were observed in the zanamivir group, as were reductions in fever (14% versus 88% in placebo, P < 0.05), upper respiratory tract illness (0% versus 100% in placebo, P < 0.005), total symptom scores (1 versus 44 [median] in placebo, P < 0.005), and nasal-discharge weight (3.9 g versus 17.5 g [median] in placebo, P < 0.005).",Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390212/),log10,0,51793,DB00558,Zanamivir
,10390212,areas under the curve,"Reductions in the frequency of viral shedding (0% versus 100% in placebo, P < 0.005) and seroconversion (14% versus 100% in placebo, P < 0.005) and decreases in viral titer areas under the curve (0 versus 11.6 [median] log10 TCID50. day/ml in placebo, P < 0.005) were observed in the zanamivir group, as were reductions in fever (14% versus 88% in placebo, P < 0.05), upper respiratory tract illness (0% versus 100% in placebo, P < 0.005), total symptom scores (1 versus 44 [median] in placebo, P < 0.005), and nasal-discharge weight (3.9 g versus 17.5 g [median] in placebo, P < 0.005).",Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390212/),tci,11.6,51794,DB00558,Zanamivir
,10390212,concentrations,"Zanamivir was detectable in nasal lavage samples collected on days 2 and 4 (unadjusted median concentrations, 10.5 and 12.0 ng/ml of nasal wash, respectively).",Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390212/),[ng] / [ml],10.5,51795,DB00558,Zanamivir
,10390212,concentrations,"Zanamivir was detectable in nasal lavage samples collected on days 2 and 4 (unadjusted median concentrations, 10.5 and 12.0 ng/ml of nasal wash, respectively).",Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390212/),[ng] / [ml],12.0,51796,DB00558,Zanamivir
,23613954,t(max),Rapid uptake (t(max) of 5 min) and a C(max) of over 7200 ng/mL was achieved.,Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23613954/),min,5,64273,DB00558,Zanamivir
over,23613954,C(max),Rapid uptake (t(max) of 5 min) and a C(max) of over 7200 ng/mL was achieved.,Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23613954/),[ng] / [ml],7200,64274,DB00558,Zanamivir
,22526307,concentrations,"Mean laninamivir concentrations in ELF, calculated using the first BAL fluids and BAL fluids collected 4 h after inhaled administration, were 8.57 and 2.40 μg/ml, respectively.","Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526307/),,8.57,107276,DB00558,Zanamivir
,22526307,concentrations,"Mean laninamivir concentrations in ELF, calculated using the first BAL fluids and BAL fluids collected 4 h after inhaled administration, were 8.57 and 2.40 μg/ml, respectively.","Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526307/),,2.40,107277,DB00558,Zanamivir
,21263045,half-life,A clinical 2.5-h half-life and an artificially prolonged 8-h half-life were simulated for zanamivir.,Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263045/),h,2.5,133938,DB00558,Zanamivir
,21263045,half-life,A clinical 2.5-h half-life and an artificially prolonged 8-h half-life were simulated for zanamivir.,Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263045/),h,8,133939,DB00558,Zanamivir
,21263045,50% inhibitory concentration [IC(50)],"Zanamivir inhibited viral release (50% inhibitory concentration [IC(50)], 0.0168 mg/liter; maximum extent of inhibition, 0.990).",Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263045/),[mg] / [l],0.0168,133940,DB00558,Zanamivir
,21263045,maximum extent of inhibition,"Zanamivir inhibited viral release (50% inhibitory concentration [IC(50)], 0.0168 mg/liter; maximum extent of inhibition, 0.990).",Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263045/),,0.990,133941,DB00558,Zanamivir
,22795831,IC(50),"Compound D26 exerts the most potency, with IC(50) values of 0.58 and 2.72 μM against N2 and N1, respectively.",Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22795831/),μM,0.58,134917,DB00558,Zanamivir
,22795831,IC(50),"Compound D26 exerts the most potency, with IC(50) values of 0.58 and 2.72 μM against N2 and N1, respectively.",Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22795831/),μM,2.72,134918,DB00558,Zanamivir
,10429838,maximum drug concentration,"Approximately 2% of the dose was absorbed; the median maximum drug concentration in serum was 15 micrograms/L, and occurred around 1.75 hours after inhalation.",Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10429838/),[μg] / [l],15,147569,DB00558,Zanamivir
,23489210,AUC0-∞,"The mean AUC0-∞ values after single intravenous administration of 100, 300 and 600 mg were 16768, 53462 and 100400 ng·h/mL, respectively, demonstrating dose proportionality.",The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489210/),[h·ng] / [ml],16768,163105,DB00558,Zanamivir
,23489210,AUC0-∞,"The mean AUC0-∞ values after single intravenous administration of 100, 300 and 600 mg were 16768, 53462 and 100400 ng·h/mL, respectively, demonstrating dose proportionality.",The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489210/),[h·ng] / [ml],53462,163106,DB00558,Zanamivir
,23489210,AUC0-∞,"The mean AUC0-∞ values after single intravenous administration of 100, 300 and 600 mg were 16768, 53462 and 100400 ng·h/mL, respectively, demonstrating dose proportionality.",The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489210/),[h·ng] / [ml],100400,163107,DB00558,Zanamivir
,10429835,half-life,"The elimination of zanamivir from the serum was a first-order process with a half-life of approximately 2 hours and, at 16 L, the volume of distribution was similar to that of extracellular water.","Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10429835/),h,2,178989,DB00558,Zanamivir
,10429835,absolute oral bioavailability,"The absolute oral bioavailability of zanamivir was low, averaging 2%.","Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10429835/),%,2,178990,DB00558,Zanamivir
,10429835,serum half-life,"The median serum half-life ranged between 2.5 and 5.05 hours, suggesting that the elimination rate is limited by absorption.","Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10429835/),h,2.5 and 5.05,178991,DB00558,Zanamivir
,20145259,half-life,"CS-8958 disappeared from plasma with a half-life of about 2 hours, although laninamivir was slowly eliminated from the body, lasting for even up to 144 hours after administration with a half-life of about 3 days.","Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145259/),h,2,182400,DB00558,Zanamivir
,20145259,half-life,"CS-8958 disappeared from plasma with a half-life of about 2 hours, although laninamivir was slowly eliminated from the body, lasting for even up to 144 hours after administration with a half-life of about 3 days.","Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145259/),d,3,182401,DB00558,Zanamivir
,20145259,cumulative urinary excretion amounts,"The cumulative urinary excretion amounts of CS-8958 and laninamivir were 2.3% to 3.6% and 10.7% to 14.6% of the dose, respectively.","Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145259/),%,2.3,182402,DB00558,Zanamivir
,20145259,cumulative urinary excretion amounts,"The cumulative urinary excretion amounts of CS-8958 and laninamivir were 2.3% to 3.6% and 10.7% to 14.6% of the dose, respectively.","Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145259/),%,3.6,182403,DB00558,Zanamivir
,20145259,cumulative urinary excretion amounts,"The cumulative urinary excretion amounts of CS-8958 and laninamivir were 2.3% to 3.6% and 10.7% to 14.6% of the dose, respectively.","Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145259/),%,10.7,182404,DB00558,Zanamivir
,20145259,cumulative urinary excretion amounts,"The cumulative urinary excretion amounts of CS-8958 and laninamivir were 2.3% to 3.6% and 10.7% to 14.6% of the dose, respectively.","Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145259/),%,14.6,182405,DB00558,Zanamivir
,23091189,rate constant,"Furthermore, after additional incubation in drug-free medium, the intracellular laninamivir was released very slowly into the medium with an estimate rate constant of 0.0707 h(-1), which was regarded as a rate-limiting step in the cellular retention.",Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23091189/),1/[h],0.0707,207797,DB00558,Zanamivir
,23553534,ΔΔQTcF,"The maximum ΔΔQTcF value for zanamivir 1200 mg was 1.73 msec (90% CI -0.40 to 3.87 msec), which was observed within 30 minutes after dosing, and 11.21 msec (90% CI 8.81-13.60) for moxifloxacin, observed at 4 hours after dosing.",Effect of intravenous zanamivir on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23553534/),ms,1.73,207861,DB00558,Zanamivir
,23553534,ΔΔQTcF,"The maximum ΔΔQTcF value for zanamivir 1200 mg was 1.73 msec (90% CI -0.40 to 3.87 msec), which was observed within 30 minutes after dosing, and 11.21 msec (90% CI 8.81-13.60) for moxifloxacin, observed at 4 hours after dosing.",Effect of intravenous zanamivir on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23553534/),ms,11.21,207862,DB00558,Zanamivir
,23330908,IC(50),"Compound 9f exerts the most potency, with IC(50) value of 0.013, 0.001, and 0.09 μM against H3N2, H5N1, and H1N1, which is similar to that of zanamivir (H3N2 IC(50) = 0.0014 μM, H5N1 IC(50) = 0.012 μM, H1N1 IC(50) = 0.001 μM).",Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23330908/),μM,0.013,235989,DB00558,Zanamivir
,23330908,IC(50),"Compound 9f exerts the most potency, with IC(50) value of 0.013, 0.001, and 0.09 μM against H3N2, H5N1, and H1N1, which is similar to that of zanamivir (H3N2 IC(50) = 0.0014 μM, H5N1 IC(50) = 0.012 μM, H1N1 IC(50) = 0.001 μM).",Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23330908/),μM,0.001,235990,DB00558,Zanamivir
,23330908,IC(50),"Compound 9f exerts the most potency, with IC(50) value of 0.013, 0.001, and 0.09 μM against H3N2, H5N1, and H1N1, which is similar to that of zanamivir (H3N2 IC(50) = 0.0014 μM, H5N1 IC(50) = 0.012 μM, H1N1 IC(50) = 0.001 μM).",Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23330908/),μM,0.09,235991,DB00558,Zanamivir
,23330908,IC(50),"Compound 9f exerts the most potency, with IC(50) value of 0.013, 0.001, and 0.09 μM against H3N2, H5N1, and H1N1, which is similar to that of zanamivir (H3N2 IC(50) = 0.0014 μM, H5N1 IC(50) = 0.012 μM, H1N1 IC(50) = 0.001 μM).",Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23330908/),μM,0.0014,235992,DB00558,Zanamivir
,23330908,IC(50),"Compound 9f exerts the most potency, with IC(50) value of 0.013, 0.001, and 0.09 μM against H3N2, H5N1, and H1N1, which is similar to that of zanamivir (H3N2 IC(50) = 0.0014 μM, H5N1 IC(50) = 0.012 μM, H1N1 IC(50) = 0.001 μM).",Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23330908/),μM,0.012,235993,DB00558,Zanamivir
,23330908,IC(50),"Compound 9f exerts the most potency, with IC(50) value of 0.013, 0.001, and 0.09 μM against H3N2, H5N1, and H1N1, which is similar to that of zanamivir (H3N2 IC(50) = 0.0014 μM, H5N1 IC(50) = 0.012 μM, H1N1 IC(50) = 0.001 μM).",Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23330908/),μM,0.001,235994,DB00558,Zanamivir
,20146556,half-life,"After intratracheal administration of CS-8958, plasma R-125489 concentration was slowly eliminated, and its half-life (14.1 h) was considerably longer than that after intravenous administration of R-125489.","Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20146556/),h,14.1,271178,DB00558,Zanamivir
